Clinical Trials Resource Center

Systemic Fungal Infections

July 28, 2003

Schering-Plough reported positive results from a phase III trial investigating NOXAFIL (posaconazole suspension), a broad-spectrum antifungal for the treatment of invasive fungal infections. Results showed subjects successfully met the study's primary endpoint of a clinical and mycological response. The study enrolled 337 subjects with invasive fungal infections resistant or refractory to standard antifungal therapies. The company expects to submit an NDA shortly for NOXAFIL to the FDA and EMEA for marketing approval.<

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.